Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer

Angiogenesis

Volumn 17, Issue 3, 2014, Pages 661-673

  Cruz Muñoz, William ^a   Di Desidero, Teresa ^a   Man, Shan ^a   Xu, Ping ^a   Jaramillo, Maria Luz ^b   Hashimoto, Kae ^a   Collins, Catherine ^b   Banville, Myriam ^b   O'Connor Mccourt, Maureen D ^b   Kerbel, Robert S ^a,c  

^a Sunnybrook Health Sciences Centre   (Canada)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Chemotherapy; Metastasis; Ovarian cancer; Pazopanib; Resistance; Topotecan

Indexed keywords

DOXORUBICIN; GEMCITABINE; IRINOTECAN; MONOCLONAL ANTIBODY DC101; PAZOPANIB; SUNITINIB; TOPOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES TUMOR CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CELL POPULATION; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG UPTAKE; DRUG WITHDRAWAL; FEMALE; GENE EXPRESSION PROFILING; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; METRONOMIC DRUG ADMINISTRATION; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVARY CANCER; OVARY METASTASIS; PHENOTYPE; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR CELL LINE; TUMOR GROWTH; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; CANCER STAGING; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IC50; METASTASIS; ORAL DRUG ADMINISTRATION; OVARIAN NEOPLASMS; PATHOLOGY; SCID MOUSE; TREATMENT OUTCOME;

MUS;

ADMINISTRATION, METRONOMIC; ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; MICE, SCID; NEOPLASM METASTASIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PYRIMIDINES; SULFONAMIDES; TOPOTECAN; TREATMENT OUTCOME;

EID: 84903887694     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-014-9422-9     Document Type: Article

References (47)

1. Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4(6):423-436
2. Pasquier E, Kavallaris M, Andre N (2010) Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 7(8):455-465
3. Rapisarda A et al (2004) Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 64(19):6845-6848
4. Lee K et al (2009) Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci USA 106(7):2353-2358
5. Folkins C et al (2009) Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res 69(18):7243-7251
6. Martin-Padura I et al (2012) Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts. Lab Invest 92(7):952-966
7. Browder T et al (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60(7):1878-1886
8. Klement G et al (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105(8):R15-R24
9. Daenen LG et al (2009) Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models. Mol Cancer Ther 8(10):2872-2881
10. Shaked Y et al (2005) Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 106(9):3058-3061
11. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3(10):721-732
12. Munoz R et al (2006) Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res 66(7):3386-3391
13. Hashimoto K et al (2010) Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther 9(4):996-1006
14. Merritt WM et al (2009) Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther 8(16):1596-1603
15. Emmenegger U et al (2011) Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia 13(1):40-48
16. Kerbel RS (2012) Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer. J Mammary Gland Biol Neoplasia 17(3-4):229-239
17. Bocci G et al (2008) Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer 98(10):1619-1629
18. Shen J et al (2009) Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid. Cancer Res 69(14):5885-5892
19. Hubbard KE et al (2009) Application of a highly specific and sensitive fluorescent HPLC method for topotecan lactone in whole blood. Biomed Chromatogr 23(7):707-713
20. Folkins C et al (2007) Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 67(8):3560-3564
21. Mizuno H, Kitada K, Nakai K, Sarai A (2009) PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genomics 2:18
22. McFadyen MC et al (2001) Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. Br J Cancer 85(2):242-246
23. Garcia AA et al (2008) Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 26(1):76-82
24. Dellapasqua S et al (2008) Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 26(30):4899-4905
25. Bottini A et al (2006) Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol 24(22):3623-3628
26. Koopman M et al (2013) Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): the phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 31:Abstr 3502
27. Miklos GL (2012) Bevacizumab in neoadjuvant treatment for breast cancer. N Engl J Med 366(17):1638 (author reply 1639-40)
28. Montero AJ, Vogel C (2012) Fighting fire with fire: rekindling the bevacizumab debate. N Engl J Med 366(4):374-375
29. Dawood S et al (2012) The use of bevacizumab among women with metastatic breast cancer: a survey on clinical practice and the ongoing controversy. Cancer 118(11):2780-2786
30. Aogi K et al (2011) First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study. Breast Cancer Res Treat 129(3):829-838
31. Thomssen C et al (2012) First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study. Oncology 82(4):218-227
32. Smith I et al (2011) Final overall survival results and effect of prolonged (≥1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial. Breast Cancer Res Treat 130(1):133-143
33. Barrios CH et al (2010) Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 121(1):121-131
34. Bergh J, Greil R, Voytko N (2011) Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC). J Clin Oncol 28:LBA 1010
35. Merritt WM et al (2010) Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol Cancer Ther 9(4):985-995
36. Kumar S et al (2011) Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin Cancer Res 17(17):5656-5667
37. Hackl C et al (2013) Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. Gut 62(2):259-271
38. Goh F, Sambanis A (2011) In vivo noninvasive monitoring of dissolved oxygen concentration within an implanted tissue-engineered pancreatic construct. Tissue Eng Part C Methods 17(9):887-894
39. Kato H et al (2004) A randomized trial of adjuvant chemotherapy with Uracil-Tegafur for adenocarcinoma of the lung. New Engl J Med 350:1713-1721
40. Garcia et al (2008) Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and princess Margaret hospital phase II consortia. J Clin Oncol 26:76-82
41. Dellapasqua et al (2008) Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 26:4899-4905
42. Berendsen HH et al (1988) Characterization of three small cell lung cancer cell lines established from one patient during longitudinal follow-up. Cancer Res 48:6891-6899
43. Kuczynski et al (2013) Drug rechallenge and treatment beyond progression in oncology: examples, mechanisms and implications of reversible drug resistance. Nature Rev Clin Oncol 10:571-587
44. Rochat B et al (2001) Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther 296(2):537-541
45. Wittig R et al (2002) Candidate genes for cross-resistance against DNA-damaging drugs. Cancer Res 62(22):6698-6705
46. Oshita SE et al (2010) The small heat shock protein HspB2 is a novel anti-apoptotic protein that inhibits apical caspase activation in the extrinsic apoptotic pathway. Breast Cancer Res Treat 124(2):307-315
47. Langbein S et al (2006) Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer 94(4):578-585